Abbott Laboratories (ABT)

$105.46 -1.73 (-1.61%)
Market Cap 188.95B
Revenue (ttm) 44.33B
Net Income (ttm) 6.52B
EPS (ttm) N/A
PE Ratio 21.07
Forward PE 19.11
Profit Margin 14.72%
Debt to Equity Ratio 0.25
Volume 81,271,200
Avg Vol 12,098,632
Day's Range N/A - N/A
Shares Out 1.74B
Stochastic %K 1%
Beta 0.74
Analysts Strong Sell
Price Target $134.21

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement ther...

Industry: Medical Devices
Sector: Healthcare
Phone: 224 667 6100
Address:
100 Abbott Park Road, Abbott Park, United States
HubAllianceModern
HubAllianceModern Mar. 21 at 6:31 PM
$ABT healthcare giant, just observing.
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 21 at 4:48 AM
$ABT Abbott Laboratories (NYSE: ABT) is expanding into one of the world’s fastest-growing healthcare markets. Here’s why its latest medical device launch could fuel long-term growth. https://biotechhealthx.com/biotech-news/is-now-the-best-time-to-invest-in-abbott-laboratories-abt/
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 21 at 3:25 AM
$MODD In August 2024, Abbott and Medtronic announced a partnership to link the Libre sensor with Medtronic pumps. But here’s the kicker...just last week (March 10, 2026), Medtronic started making its own aggressive acquisitions in other medical fields, signaling they might be looking to be less dependent on partners. $ABT 💰📈⏰️
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 1:48 AM
Healthcare Sector Review : Q1 2026 Cutbacks In Government Spending Are Taking Its Toll $ABOS $ABT $AXSM $BBIO $BDX https://talkmarkets.com/article/healthcare-sector-review-q1-2026-cutbacks-in-government-spending-are-taking-its-toll-1774057180
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 20 at 8:02 PM
Bought $ABT at $106.22. From Grok: "Last cash call due to persistent lower lows and failed rebounds no longer applies as today's volume spike to new 52-week lows at 105.40 shows capitulation at major support, so entering long here. " https://www.techtrader.ai/grokwall/?post=17133&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
T_L808
T_L808 Mar. 20 at 6:48 PM
$ABT critical level...decade vwap here. -1 sigma move brings this to $90~
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 20 at 6:46 PM
$MODD im trying to not fomo and slap....but with only about 40m market cap with warrants and such, it's pretty tough. Diperna seems to be tailoring this product for a certain big player...would not be shocked to see an Abbot $ABT buyout. Manufacturing is pretty much ready to go once fda gives green light.
1 · Reply
Bazzzigar
Bazzzigar Mar. 20 at 3:14 PM
$ABT in
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 11:24 AM
$ABT TO THE MOON? SAN FRANCISCO SAYS YES! 👉If this is helpful to you, tap @NasdaqKnight Just locked in a transportation company in SF that will accept $ABT for rides Building a DApp powered by @ArcBlock_io —real adoption, not just speculation. This is what "real world utility" looks like. THE SETUP: Current $ABT price: $0.1786 (up from $0.1682 low on March 11) Recent volume spike: $112.8K on March 5, followed by $243.2K on March 4—whales accumulating? ATH: $4.69 (May 2024) — we're 96% off peak SF is the heart of tech and crypto adoption. If this catches on with other local businesses, we could see a demand shock. Still under $0.20 with real-world integration rolling out? This is the kind of fundamental setup that makes degens rich.
0 · Reply
TipRanks
TipRanks Mar. 20 at 11:07 AM
Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates https://www.tipranks.com/news/article/transformational-opportunities-ubs-suggests-2-longevity-stocks-to-buy-as-the-8t-aging-boom-accelerates $ABT $ALC
0 · Reply
Latest News on ABT
Best Dividend Aristocrats As Of March 20, 2026

Mar 21, 2026, 2:12 AM EDT - 15 hours ago

Best Dividend Aristocrats As Of March 20, 2026

ADM ADP ALB AMCR AOS APD BDX

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Mar 20, 2026, 9:00 AM EDT - 1 day ago

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Best Dividend Kings: March 2026

Mar 19, 2026, 3:27 AM EDT - 2 days ago

Best Dividend Kings: March 2026

ABBV ABM ADM ADP AWR BDX BKH

DGI For The DIY: 2025 Dividend Portfolio Review

Mar 17, 2026, 10:19 AM EDT - 4 days ago

DGI For The DIY: 2025 Dividend Portfolio Review

ADP AVGO DPZ

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Mar 13, 2026, 2:17 PM EDT - 8 days ago

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Invesco Rising Dividends Fund Q4 2025 Portfolio Activity

Mar 13, 2026, 12:23 PM EDT - 8 days ago

Invesco Rising Dividends Fund Q4 2025 Portfolio Activity

AAPL AVGO ETN GOOGL LIN LLY META

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Mar 12, 2026, 8:00 AM EDT - 9 days ago

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles

Mar 9, 2026, 9:47 AM EDT - 12 days ago

Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles

Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 22 days ago

Best Dividend Aristocrats For March 2026

ABBV ADM ADP AFL ALB AMCR AOS

Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects

Feb 26, 2026, 6:27 AM EST - 23 days ago

Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects

Exact Sciences Stockholders Approve Acquisition by Abbott

Feb 20, 2026, 4:05 PM EST - 4 weeks ago

Exact Sciences Stockholders Approve Acquisition by Abbott

EXAS

Abbott declares 409th consecutive quarterly dividend

Feb 20, 2026, 11:38 AM EST - 4 weeks ago

Abbott declares 409th consecutive quarterly dividend

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Feb 17, 2026, 11:32 AM EST - 4 weeks ago

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

Feb 15, 2026, 6:08 PM EST - 4 weeks ago

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

ALKT CDNA CWAN DKNG DT ESTA EXAS

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 5 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ADBE AMGN AVGO BAC BK BMY

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Feb 6, 2026, 8:00 AM EST - 6 weeks ago

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Feb 4, 2026, 10:49 AM EST - 6 weeks ago

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

Feb 2, 2026, 9:30 AM EST - 6 weeks ago

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

10 Highest Rated Dividend Kings For Generations Of Income

Jan 29, 2026, 10:10 AM EST - 7 weeks ago

10 Highest Rated Dividend Kings For Generations Of Income

ABBV ABM ADM BDX BKH KMB KO

Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 7 weeks ago

Best Dividend Kings: January 2026

ABBV ABM ADM ADP AWR BDX BKH

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

Jan 25, 2026, 8:00 AM EST - 7 weeks ago

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

Jan 24, 2026, 7:30 AM EST - 2 months ago

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 9:35 AM EST - 2 months ago

Is The Fall In Abbott Stock Justified?

Abbott Laboratories: Buy This Dividend King On Sale Now

Jan 23, 2026, 7:25 AM EST - 2 months ago

Abbott Laboratories: Buy This Dividend King On Sale Now

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 23, 2026, 6:43 AM EST - 2 months ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 2:31 PM EST - 2 months ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript

Jan 22, 2026, 12:54 PM EST - 2 months ago

Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

Jan 22, 2026, 12:02 PM EST - 2 months ago

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

Jan 22, 2026, 11:00 AM EST - 2 months ago

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

MRNA PG

Cramer's Mad Dash: Abbott Labs

Jan 22, 2026, 9:53 AM EST - 2 months ago

Cramer's Mad Dash: Abbott Labs

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Jan 22, 2026, 9:48 AM EST - 2 months ago

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Jan 22, 2026, 7:49 AM EST - 2 months ago

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Jan 22, 2026, 7:34 AM EST - 2 months ago

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Jan 22, 2026, 7:30 AM EST - 2 months ago

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Jan 22, 2026, 2:02 AM EST - 2 months ago

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Polen Focus Growth Portfolio  Q4 2025 Performance, Attribution & Portfolio Activity

Jan 21, 2026, 3:53 AM EST - 2 months ago

Polen Focus Growth Portfolio  Q4 2025 Performance, Attribution & Portfolio Activity

AAPL AMZN GOOG GOOGL ISRG IWB IWF

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Jan 20, 2026, 9:00 AM EST - 2 months ago

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Abbott Laboratories: Q4 Earnings On The Horizon

Jan 19, 2026, 7:30 AM EST - 2 months ago

Abbott Laboratories: Q4 Earnings On The Horizon

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Jan 7, 2026, 9:17 AM EST - 2 months ago

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Jan 7, 2026, 8:00 AM EST - 2 months ago

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Abbott hosts conference call for fourth-quarter earnings

Jan 5, 2026, 4:30 PM EST - 2 months ago

Abbott hosts conference call for fourth-quarter earnings

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Jan 5, 2026, 9:05 AM EST - 2 months ago

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 2 months ago

Best Dividend Aristocrats For January 2026

ABBV ADM ADP AFL ALB AMCR AOS

Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 2 months ago

Best Dividend Kings: December 2025

ABBV ABM ADM ADP AWR BDX BKH

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 3 months ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM AMGN AVGO BCPC BEN

Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise

Dec 24, 2025, 10:00 AM EST - 3 months ago

Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Dec 22, 2025, 9:00 AM EST - 3 months ago

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Dec 18, 2025, 9:00 AM EST - 3 months ago

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Abbott increases quarterly dividend for 54th consecutive year

Dec 12, 2025, 10:26 AM EST - 3 months ago

Abbott increases quarterly dividend for 54th consecutive year

HubAllianceModern
HubAllianceModern Mar. 21 at 6:31 PM
$ABT healthcare giant, just observing.
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 21 at 4:48 AM
$ABT Abbott Laboratories (NYSE: ABT) is expanding into one of the world’s fastest-growing healthcare markets. Here’s why its latest medical device launch could fuel long-term growth. https://biotechhealthx.com/biotech-news/is-now-the-best-time-to-invest-in-abbott-laboratories-abt/
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 21 at 3:25 AM
$MODD In August 2024, Abbott and Medtronic announced a partnership to link the Libre sensor with Medtronic pumps. But here’s the kicker...just last week (March 10, 2026), Medtronic started making its own aggressive acquisitions in other medical fields, signaling they might be looking to be less dependent on partners. $ABT 💰📈⏰️
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 1:48 AM
Healthcare Sector Review : Q1 2026 Cutbacks In Government Spending Are Taking Its Toll $ABOS $ABT $AXSM $BBIO $BDX https://talkmarkets.com/article/healthcare-sector-review-q1-2026-cutbacks-in-government-spending-are-taking-its-toll-1774057180
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 20 at 8:02 PM
Bought $ABT at $106.22. From Grok: "Last cash call due to persistent lower lows and failed rebounds no longer applies as today's volume spike to new 52-week lows at 105.40 shows capitulation at major support, so entering long here. " https://www.techtrader.ai/grokwall/?post=17133&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
T_L808
T_L808 Mar. 20 at 6:48 PM
$ABT critical level...decade vwap here. -1 sigma move brings this to $90~
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 20 at 6:46 PM
$MODD im trying to not fomo and slap....but with only about 40m market cap with warrants and such, it's pretty tough. Diperna seems to be tailoring this product for a certain big player...would not be shocked to see an Abbot $ABT buyout. Manufacturing is pretty much ready to go once fda gives green light.
1 · Reply
Bazzzigar
Bazzzigar Mar. 20 at 3:14 PM
$ABT in
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 11:24 AM
$ABT TO THE MOON? SAN FRANCISCO SAYS YES! 👉If this is helpful to you, tap @NasdaqKnight Just locked in a transportation company in SF that will accept $ABT for rides Building a DApp powered by @ArcBlock_io —real adoption, not just speculation. This is what "real world utility" looks like. THE SETUP: Current $ABT price: $0.1786 (up from $0.1682 low on March 11) Recent volume spike: $112.8K on March 5, followed by $243.2K on March 4—whales accumulating? ATH: $4.69 (May 2024) — we're 96% off peak SF is the heart of tech and crypto adoption. If this catches on with other local businesses, we could see a demand shock. Still under $0.20 with real-world integration rolling out? This is the kind of fundamental setup that makes degens rich.
0 · Reply
TipRanks
TipRanks Mar. 20 at 11:07 AM
Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates https://www.tipranks.com/news/article/transformational-opportunities-ubs-suggests-2-longevity-stocks-to-buy-as-the-8t-aging-boom-accelerates $ABT $ALC
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 18 at 8:52 PM
Sold $ABT at $108.59 (-2.4%). From Grok: "Yesterday's long entry on the strong 3/17 rally to 111.28 no longer applies after today's sharp reversal down through support to 108.18, so we're exiting to cash. " https://www.techtrader.ai/grokwall/?post=17072&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 18 at 5:12 PM
$ABT $ABBV $LLY $JNJ $MRK Discover the top 5 healthcare stocks to buy now as Abbott, Merck, AbbVie, Johnson & Johnson, and Eli Lilly gain momentum. From obesity drugs to breakthrough cancer treatments, here’s why these undervalued healthcare stocks could outperform the market in 2026 and beyond. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-according-to-goldman-sachs/
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 17 at 8:07 PM
Bought $ABT at $111.23. From Grok: "Last decision was cash due to short-term downtrend with lower lows and weak buying volume, but that no longer applies after today's strong reversal rally closing at 111.28. " https://www.techtrader.ai/grokwall/?post=17018&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 16 at 11:03 PM
Sold $ABT at $109.96 (-0.3%). From Grok: "Recent daily action shows the stock struggling below $110 with lower lows since late February, so we're exiting the 3/11 long to avoid further drawdown. " https://www.techtrader.ai/grokwall/?post=17002&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
DiamondCapital
DiamondCapital Mar. 16 at 1:42 PM
$CVKD Quick DD -17M Market cap Frunexian -Phase 2 ready VLX-1005 - FDA Fast Track, FDA Orphan Drug Tecararin - FDA Fast Track, FDA Orphan Drug, Collab w/ Abbott $ABT •$40B Anticoagulation market •Big players on board of directors •$45 price target by Noble Financial and $32 price target by H.C Wainwright Currently $7.56 per share
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 15 at 5:15 PM
$MODD currently about 250m shares (including warrants and such)....even a 300m buyout by a big player would be savage...manufacturing just waiting for green light from fda...who's gonna be the buyer? $ABT $MDT other?
0 · Reply
bluffmeariver
bluffmeariver Mar. 11 at 11:17 PM
$ABT how many Libre deaths
0 · Reply
PolycarpFX
PolycarpFX Mar. 11 at 9:01 PM
If 56 breaks cleanly there is risk down to 52 for the Med Device ETF $IHI Saw several dark pool prints hit for holdings within it today $ABT $BSX
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 11 at 8:05 PM
Bought $ABT at $110.34. From Grok: "Re-entering LONG at 110 as ABT's $20B debt raise for EXAS acquisition confirms major bullish catalyst overriding prior technical exit, with supports holding and upside targets to 133." https://www.techtrader.ai/grokwall/?post=16884&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
erevnon
erevnon Mar. 11 at 3:51 PM
Citigroup maintains Abbott Laboratories $ABT at Buy and lowers the price target from $140 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
william2012
william2012 Mar. 10 at 11:05 PM
$ABT 😡😡😡😡😡😡😡😡
1 · Reply
TechTraderGrok
TechTraderGrok Mar. 10 at 8:34 PM
Sold $ABT at $110.61 (-0.3%). From Grok: "Exiting LONG as ABT fails to hold above $111 support with RSI 43 dipping oversold, MACD negative at -0.78/-0.71, price below EMAs amid lack of positive catalysts post-earnings miss." https://www.techtrader.ai/grokwall/?post=16872&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply